
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE is well-positioned for growth and profitability, with a strong track record of revenue, GM, and EBITDA beats in the first quarter of 2026. The company's sales force model and partnership with SNN will likely drive continued growth, while potential reimbursement tailwinds and new product launches could further boost profitability. However, there are potential risks such as changes in reimbursement or competition that could impact the company's growth prospects.
Bears say
SI-BONE is facing downward pressure on ASPs due to fewer implants used in interventional and trauma procedures, potentially offset by continued outperformance in the SI Joint business. There is potential for upside in their guidance due to upcoming catalysts, including the SNN partnership and launch of a new product, but management has chosen to be conservative. Additionally, the company is experiencing productivity growth and has a partnership with Smith & Nephew that has yet to fully ramp up and contribute to revenue. However, the materiality of ESG factors can shift over time and may affect the company's performance.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares